The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Activation of the alternative complement pathway due to resistance of zymosan-bound.
Open accessAbstract
The surface of zymosan (Zy), by affording a protected microenvironment for C3b and the amplification convertase stabilized by properdin, P,C3b,Bb, shifts the alternative complement pathway from slow fluid phase turnover to the amplification phase of its expression. This mode of activation is in contradistinction to that of the classical pathway, which follows conversion of a proenzyme, Cl, to its active form, C1. Under conditions in which the control proteins, C3b inactivator (C3bINA) and beta1H, completely, inactivated C3b on the sheep erythrocyte intermediate, EAC4b,3b, the activity of C3b bound to Zy,ZyC3b, was diminished by only one-third. Further, when ZyC3b was converted to ZyC3b,Bb,P there was an additional point of deregulation in that the convertase was resistant to beta1H-mediated decay-dissociation while P,C3b,Bb on the sheep erythrocyte exhibited the usual susceptibility to beta1H. That Zy alone could indeed promote rapid C3 cleavage by the alternative pathway through assembly and protection of the amplification convertase on its surface was demonstrated with a mixture of alternative pathway proteins, C3,B,D,P, C3bINA, and beta1H, that had each been purified to homogeneity. Interaction of these proteins at one-tenth their relative serum concentrations with Zy permitted low-grade inactivation of C3 and B to advance to the level of amplification after a 15 min lag period. Because the reaction of the purified proteins proceeded spontaneously when either regulatory protein was deleted, the effect of Zy was attributed to deregulation rather than to conversion of one of the proteins to a specific initiating state. The alternative pathway, through the normal presence of D, interacts with a microbial surface, such as Zy, to amplify deposition of C3b by circumvention of endogenous regulatory mechanisms, thereby augmenting host defense.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weber, K., & Osborn, M. (1969) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)94333-4 · Cited by 20,298
Pillemer, L., Blum, L., Lepow, I. H., Ross, O. A., Todd, E. W., & Wardlaw, A. C. (1954) · Science · doi:10.1126/science.120.3112.279 · Cited by 938
Modulation of the alternative complement pathways by beta 1 H globulin.
Whaley, K., & Ruddy, S. (1976) · The Journal of experimental medicine · doi:10.1084/jem.144.5.1147 · Cited by 583
Control of the amplification convertase of complement by the plasma protein beta1H.
Weiler, J. M., Daha, M. R., Austen, K. F., & Fearon, D. T. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.9.3268 · Cited by 570
Self-citationProperdin: binding to C3b and stabilization of the C3b-dependent C3 convertase.
Fearon, D. T., & Austen, K. F. (1975) · The Journal of experimental medicine · doi:10.1084/jem.142.4.856 · Cited by 481
Self-citationCHROMATOGRAPHIC RESOLUTION OF THE FIRST COMPONENT OF HUMAN COMPLEMENT INTO THREE ACTIVITIES
Lepow, I. H., Naff, G. B., Todd, E. W., Pensky, J., & Hinz, C. F. (1963) · The Journal of Experimental Medicine · doi:10.1084/jem.117.6.983 · Cited by 378
C3 PROACTIVATOR CONVERTASE AND ITS MODE OF ACTION
Müller-Eberhard, H. J., & Götze, O. (1972) · The Journal of Experimental Medicine · doi:10.1084/jem.135.4.1003 · Cited by 324
Complement dependent immune phagocytosis
Gigli, I., & Nelson, R. A. (1968) · Experimental Cell Research · doi:10.1016/0014-4827(68)90158-4 · Cited by 289
Serum C′3 Lytic System in Patients with Glomerulonephritis
Spitzer, R. E., Vallota, E. H., Forristal, J., Sudora, E., Stitzel, A., Davis, N. C., & West, C. D. (1969) · Science · doi:10.1126/science.164.3878.436 · Cited by 261
Fearon, D. T., Austen, K. F., & Ruddy, S. (1973) · The Journal of Experimental Medicine · doi:10.1084/jem.138.6.1305 · Cited by 178
Self-citationPROPERDIN FACTOR D: CHARACTERIZATION OF ITS ACTIVE SITE AND ISOLATION OF THE PRECURSOR FORM
Fearon, D. T., Austen, K. F., & Ruddy, S. (1974) · The Journal of Experimental Medicine · doi:10.1084/jem.139.2.355 · Cited by 118
Self-citationInactivator of the Third Component of Complement as an Inhibitor in the Properdin Pathway
Alper, C. A., Rosen, F. S., & Lachmann, P. J. (1972) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.69.10.2910 · Cited by 103
Initiation of C3 Cleavage in the Alternative Complement Pathway
Fearon, D. T., & Austen, K. F. (1975) · The Journal of Immunology · doi:10.4049/jimmunol.115.5.1357 · Cited by 71
Self-citationSchreiber, R. D., Götze, O., & Müller‐Eberhard, H. J. (1976) · The Journal of Experimental Medicine · doi:10.1084/jem.144.4.1062 · Cited by 60
Daha, M. R., Fearon, D. T., & Austen, K. F. (1976) · The Journal of Immunology · doi:10.4049/jimmunol.116.2.568 · Cited by 26
Self-citation
Cited by
Long-Circulating and Target-Specific Nanoparticles: Theory to Practice
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01494-7 · Cited by 3,515
Weisman, H. F., Bartow, T., Leppo, M. K., Marsh, H. C., Carson, G. R., Concino, M. F., Boyle, M. P., Roux, K. H., Weisfeldt, M. L., & Fearon, D. T. (1990) · Science · doi:10.1126/science.2371562 · Cited by 977
Self-citationInfectious diseases associated with complement deficiencies
Figueroa, J. E., & Densen, P. (1991) · Clinical Microbiology Reviews · doi:10.1128/cmr.4.3.359 · Cited by 729
Fearon, D. (1980) · The Journal of Experimental Medicine · doi:10.1084/jem.152.1.20 · Cited by 644
Self-citationCutaneous tissue repair: Basic biologic considerations. I
Clark, R. A. F. (1985) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(85)70213-7 · Cited by 588
Metadata
- Authors
- Fearon, D. T., & Austen, K. F.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1977-04
- Volume
- 74
- Issue
- 4
- Pages
- 1683-1687
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1538060285
- Cited by
- 284
- References
- 15
- FWCI
- 7.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.